A PHASE I STUDY OF THE CEACAM5 x CD3 ANTIBODY NILK-2301 IN COLORECTAL CANCER
Phase 1
Recruiting
- Conditions
- OCALLY ADVANCED OR METASTATIC LOW TUMOR VOLUME COLORECTAL CANCERTherapeutic area: Diseases [C] - Digestive System Diseases [C06]
- Registration Number
- CTIS2023-508058-24-01
- Lead Sponsor
- ovImmune S.A.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 12
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method